Tian-Bao Huang1, Chuan-Peng Dong2, Guang-Chen Zhou1, Sheng-Ming Lu1, Yang Luan1, Xiao Gu1, Lei Liu3, Xue-Fei Ding4. 1. Department of Urology, Northern Jiangsu People's Hospital, College of Clinical Medicine, Yangzhou University, No. 98 West Nantong Road, Yangzhou, 225001, Jiangsu Province, China. 2. Institute of Biomedical Science, Shanghai Medical College, Fudan University, Dong'an Rd 131, Xuhui District, Shanghai, China. 3. Institute of Biomedical Science, Shanghai Medical College, Fudan University, Dong'an Rd 131, Xuhui District, Shanghai, China. liulei_sibs@163.com. 4. Department of Urology, Northern Jiangsu People's Hospital, College of Clinical Medicine, Yangzhou University, No. 98 West Nantong Road, Yangzhou, 225001, Jiangsu Province, China. dingxf_sbyy@163.com.
Abstract
PURPOSES: Growing evidences showed that lncRNAs abnormally expressed in cancer tissues and played irreplaceable roles in tumorigenesis, progression and metastasis. In present study, we aimed to identify lncRNA expression signature that can predict biochemical recurrence-free (BCR-free) survival of prostate cancer (PCa) patients. METHODS: A total of 291 patients with pathologic confirmed PCa in The Cancer Genome Atlas dataset were recruited and included. With the specific risk score formula, patients were further classified into high-risk group and low-risk group. Kaplan-Meier survival analyses and Cox regression analyses were performed to determine the association between lncRNA signature and survival outcomes. Gene Set Enrichment Analysis (GSEA) was carried out to identify the potentially associated biological processes and signaling pathway. RESULTS: Overall, 126 differentially expressed lncRNAs were found with more than twofold changes and p value of FDR <0.01. Among which, four lncRNAs were identified to be significantly associated with BCR-free survival. Then, using a risk score based on the signature of these four lncRNAs, we divided the patients into low-risk and high-risk groups with significantly different BCR-free survival and disease-free survival. Further multivariate Cox regression analyses revealed that the four-lncRNA signature was independent of age, AJCC T stage, lymphonodus status, Gleason score, margin and adjuvant postoperative radiotherapy. GSEA suggested that this signature was involved in cell proliferation. CONCLUSIONS: In present study, a novel four-lncRNA signature that is useful in survival prediction in PCa patients was developed. If validated, this lncRNA signature might assist in selecting high-risk subpopulation who need more aggressive therapeutic intervention. The clinical implications and the mechanism of these four lncRNAs deserve further investigation in future studies.
PURPOSES: Growing evidences showed that lncRNAs abnormally expressed in cancer tissues and played irreplaceable roles in tumorigenesis, progression and metastasis. In present study, we aimed to identify lncRNA expression signature that can predict biochemical recurrence-free (BCR-free) survival of prostate cancer (PCa) patients. METHODS: A total of 291 patients with pathologic confirmed PCa in The Cancer Genome Atlas dataset were recruited and included. With the specific risk score formula, patients were further classified into high-risk group and low-risk group. Kaplan-Meier survival analyses and Cox regression analyses were performed to determine the association between lncRNA signature and survival outcomes. Gene Set Enrichment Analysis (GSEA) was carried out to identify the potentially associated biological processes and signaling pathway. RESULTS: Overall, 126 differentially expressed lncRNAs were found with more than twofold changes and p value of FDR <0.01. Among which, four lncRNAs were identified to be significantly associated with BCR-free survival. Then, using a risk score based on the signature of these four lncRNAs, we divided the patients into low-risk and high-risk groups with significantly different BCR-free survival and disease-free survival. Further multivariate Cox regression analyses revealed that the four-lncRNA signature was independent of age, AJCC T stage, lymphonodus status, Gleason score, margin and adjuvant postoperative radiotherapy. GSEA suggested that this signature was involved in cell proliferation. CONCLUSIONS: In present study, a novel four-lncRNA signature that is useful in survival prediction in PCa patients was developed. If validated, this lncRNA signature might assist in selecting high-risk subpopulation who need more aggressive therapeutic intervention. The clinical implications and the mechanism of these four lncRNAs deserve further investigation in future studies.
Authors: Steven Joniau; Alberto Briganti; Paolo Gontero; Giorgio Gandaglia; Lorenzo Tosco; Steffen Fieuws; Bertrand Tombal; Giansilvio Marchioro; Jochen Walz; Burkhard Kneitz; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Markus Graefen; Paul van Cangh; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn Journal: Eur Urol Date: 2014-01-25 Impact factor: 20.096
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Nicole M White; Shuang G Zhao; Jin Zhang; Emily B Rozycki; Ha X Dang; Sandra D McFadden; Abdallah M Eteleeb; Mohammed Alshalalfa; Ismael A Vergara; Nicholas Erho; Jeffrey M Arbeit; Robert Jeffrey Karnes; Robert B Den; Elai Davicioni; Christopher A Maher Journal: Eur Urol Date: 2016-07-22 Impact factor: 20.096
Authors: Zhou Du; Teng Fei; Roel G W Verhaak; Zhen Su; Yong Zhang; Myles Brown; Yiwen Chen; X Shirley Liu Journal: Nat Struct Mol Biol Date: 2013-06-02 Impact factor: 15.369
Authors: John R Prensner; Anirban Sahu; Matthew K Iyer; Rohit Malik; Benjamin Chandler; Irfan A Asangani; Anton Poliakov; Ismael A Vergara; Mohammed Alshalalfa; Robert B Jenkins; Elai Davicioni; Felix Y Feng; Arul M Chinnaiyan Journal: Oncotarget Date: 2014-03-30
Authors: Francesco Crea; Luca Quagliata; Agnieszka Michael; Hui Hsuan Liu; Paolo Frumento; Arun A Azad; Hui Xue; Larissa Pikor; Akira Watahiki; Rudolf Morant; Serenella Eppenberger-Castori; Yuwei Wang; Abhijit Parolia; Kim A Lennox; Wan L Lam; Martin Gleave; Kim N Chi; Hardev Pandha; Yuzhuo Wang; Cheryl D Helgason Journal: Mol Oncol Date: 2015-12-22 Impact factor: 6.603
Authors: Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera Journal: Oncotarget Date: 2018-04-17